Paper33850002
Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma.
Tang TT and 8 others. Mol Cancer Ther, 2021. Cited by 221 papers, by iCite.
Cite this record
ConductScience Library. Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma. Papers, record 33850002. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33850002
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Mesothelioma, Malignant | Major topic |
| TEA Domain Transcription Factors | Major topic |
| Animals | |
| Cell Proliferation | |
| Humans | |
| Lipoylation | |
| Mice | |
| Signal Transduction |
Source PubMed
Cited by152
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 221 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42867545 | Chromosome 6q mediated loss of LATS1 tumour suppression as a targetable mechanism of ultra-high-risk posterior fossa A ependymoma. | Acta Neuropathol | 2026 | https://conductscience.org/library/papers/42867545 | PubMed |
| 42806999 | Experimental assessment of computationally nominated small molecules targeting the YAP-TEAD interface in Hippo pathway-altered mesothelioma cell models. | Front Oncol | 2026 | https://conductscience.org/library/papers/42806999 | PubMed |
| 42737441 | The Crosstalk Between YAP/TAZ and Cancer Metabolism: From Mechanistic Insights to Drug Discovery. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42737441 | PubMed |
| 42664350 | LATS1/2 inactivation drives a distinct venous endothelial cell response that contributes to fibrotic remodeling of the lung. | Sci Adv | 2026 | https://conductscience.org/library/papers/42664350 | PubMed |
| 42598033 | TEAD inhibitors re-sensitize drug-resistant NF1 MPNST cells to MEK inhibitors. | MicroPubl Biol | 2026 | https://conductscience.org/library/papers/42598033 | PubMed |
| 42524518 | ZDHHC-Mediated Protein S-Palmitoylation in Cancer: Epigenetic Interfaces, Structural Logic and Therapeutic Targeting. | Int J Med Sci | 2026 | https://conductscience.org/library/papers/42524518 | PubMed |
| 42446669 | TEAD inhibitor induced switch in energy metabolism drives human podocyte injury in vitro. | Arch Toxicol | 2026 | https://conductscience.org/library/papers/42446669 | PubMed |
| 42441024 | YAP1 depletion enhances TAZ and its complexation with TEAD4 and AP-1 heterodimer C-JUN/FOSB in gastric cancer progression and metastasis. | Cancer Heterog Plast | 2026 | https://conductscience.org/library/papers/42441024 | PubMed |
| 42390936 | Extracellular matrix reprogramming by the YAP/TAZ/TGF-β2 axis drives immune exclusion in cholangiocarcinoma models. | J Clin Invest | 2026 | https://conductscience.org/library/papers/42390936 | PubMed |
| 42365001 | Covalent pan-TEAD inhibitors block YAP activity and demonstrate brain penetrance in a Hippo-dependent cancer model. | Nat Commun | 2026 | https://conductscience.org/library/papers/42365001 | PubMed |
| 42341114 | Inflammatory monocytes constrain YAP-induced cell proliferation. | Sci Adv | 2026 | https://conductscience.org/library/papers/42341114 | PubMed |
| 42338005 | A Serum lncRNA Signature Determines Oncogenic YAP Activity in Cancer Patients. | Int J Cancer | 2026 | https://conductscience.org/library/papers/42338005 | PubMed |
| 42287329 | The Hippo signaling pathway in pediatric brain tumors: molecular mechanisms and therapeutic opportunities. | Cancer Metastasis Rev | 2026 | https://conductscience.org/library/papers/42287329 | PubMed |
| 42199411 | Immunomodulatory crosstalk between GPCR and hippo signaling in cancer: implications for tumor immunity and therapeutic targeting. | Front Immunol | 2026 | https://conductscience.org/library/papers/42199411 | PubMed |
| 42128666 | STK38/L promote tissue growth and cancer by inhibiting the Hippo pathway. | Genes Dev | 2026 | https://conductscience.org/library/papers/42128666 | PubMed |
| 42125750 | TEAD inhibitors synergize with MEK, SHP2 and mTOR inhibitors in NF1 and NF2 cell lines. | MicroPubl Biol | 2026 | https://conductscience.org/library/papers/42125750 | PubMed |
| 42122155 | Targeting Autophagy to Overcome Chemoresistance and Immune Resistance in Triple-Negative Breast Cancer. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42122155 | PubMed |
| 42121934 | Research on the Hippo Pathway in Cancer. | Cells | 2026 | https://conductscience.org/library/papers/42121934 | PubMed |
| 41938591 | The Roles of Protein S-Palmitoylation in Cancers: From Dynamic Modulation to Therapeutic Potential. | Cancer Commun (Lond) | 2026 | https://conductscience.org/library/papers/41938591 | PubMed |
| 41881106 | Reduced podocyte stiffness is a feature of proteinuric kidney disease. | Kidney Int | 2026 | https://conductscience.org/library/papers/41881106 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| NF2 | 4771 | PubTator's text mining | https://conductscience.org/library/genes/4771 | NCBI Gene |
| TAFAZZIN | 6901 | PubTator's text mining | https://conductscience.org/library/genes/6901 | NCBI Gene |
| YAP1 | 10413 | PubTator's text mining | https://conductscience.org/library/genes/10413 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33850002
GET https://conductscience.org/api/papers/v1/33850002/cited_by?page=2